Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Marvell Technology Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while Marvell Technology Inc trades at $279.87 (market cap $255.84B). The key difference: Marvell Technology Inc is far larger — about 54.3× Definium Therapeutics Inc. Common Shares's market cap, and Marvell Technology Inc pays a 0.08% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Marvell Technology Inc for 42 Days on average.
| DFTX | MRVL | |
|---|---|---|
Market Cap | $4.71B | $255.84B |
Volume | 1,966,636 | 23,652,500 |
Sector | Health | Technology |
52-Week High | $48.45 | $316.43 |
52-Week Low | $10.68 | $73.73 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $3.67B | $257.20B |
Dividend Yield | — | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Marvell Technology (MRVL) trades at $274.66, down 4.3% over 24 hours, amid strong bullish technical signals and robust analyst sentiment. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at 1.1. Revenue growth accelerated to 42% in fiscal 2026, driven by data center demand, while profitability metrics like a 52.21% gross margin underscore operational strength. Recent news highlights major custom AI chip deals, including a potential $120 billion agreement with Google.
Outlook remains positive given elevated AI infrastructure spending and raised fiscal 2028 revenue guidance to $18 billion. Risks include high valuation multiples (P/E of 94.26) and dependence on hyperscaler demand. With 84% analyst buy ratings and a $327.86 consensus target, the stock offers growth potential but requires monitoring of competitive and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
